Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Unexpected Demand Triggers Supply Curb for Eisai’s ALS Med Just 3 Months after Launch; Patients Urge Early Response
March 5, 2025
-
BUSINESS Sumitomo Group Continues to Seek Best Partners for Pharma Biz
March 5, 2025
-
BUSINESS Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA
March 5, 2025
-
COMMENTARY Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
-
BUSINESS 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff
March 4, 2025
-
REGULATORY No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
-
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
-
ORGANIZATION JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
-
ORGANIZATION Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform
February 26, 2025
-
ACADEMIA 1st CP Inhibitor Approved for Sarcoma, Could This Be a Breakthrough to Treatment of More Subtypes?
February 25, 2025
-
REGULATORY Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
-
REGULATORY Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
February 20, 2025
-
BUSINESS LTL Pharma Sees 30% Drop in Gaster Sales after New LLP Coverage Rollout
February 19, 2025
-
REGULATORY Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
-
REGULATORY Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
-
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
-
BUSINESS Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
-
BUSINESS Cheplapharm Set to Expand LLP Deals to 20 APIs, Sees Opportunities Despite Headwinds
February 12, 2025
-
ORGANIZATION US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
-
BUSINESS Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen
February 10, 2025
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…